Vistagen and fuji enter exclusive negotiation agreement for a potential license to develop and commercialize vistagen's investigational menopausal hot flash therapy, ph80 nasal spray, in japan

South san francisco, calif. & tokyo--(business wire)---- $vtgn #menopause--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, and fuji pharma co., ltd. (“fuji”) (tse: 4554), a pharmaceutical company specializing in development, manufacture and marketing in the fields of women's healthcare and acute medical care, today announced they have entered into a time-.
VTGN Ratings Summary
VTGN Quant Ranking